Filing Flows › Comparisons › ACAD vs CORT
Acadia Pharmaceuticals vs Corcept Therapeutics: ACAD and CORT compared
Acadia Pharmaceuticals is the larger company: $342M of revenue in its latest quarter (Q3 2026) against $340M for Corcept Therapeutics (Q3 2026). Corcept Therapeutics is growing faster (+64% against +23% a year earlier). Corcept Therapeutics is more profitable, with an operating margin of 33.7% against 21.0%.
Where the money goes: ACAD and CORT
Acadia Pharmaceuticals (ACAD) · Q3 2026
Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart follows the revenue to costs, profit and cash.
Corcept Therapeutics (CORT) · Q3 2026
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
| Acadia Pharmaceuticals (ACAD) | Corcept Therapeutics (CORT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $342M | $340M |
| Revenue growth, Y/Y | +23% | +64% |
| Operating margin | 21.0% | 33.7% |
| Net earnings | $53.5M | $127M |
| Net margin | 15.6% | 37.2% |
| Operating cash flow | $11.5M | $143M |
| Free cash flow | $10.3M | $142M |
| Market value | $3.7B | $9.0B |
| P/E | 10.3× | 57.3× |
| Analysts’ mean target | $30.68 | $142.60 |
Where the revenue comes from
Acadia Pharmaceuticals
- Nuplazid: $202M (59%)
- Daybue: $140M (41%)
Corcept Therapeutics
- Hypercortisolism Products: $249M (73%)
- Lifyorli: $91.4M (27%)
Questions
Which is bigger, Acadia Pharmaceuticals or Corcept Therapeutics?
Acadia Pharmaceuticals is the larger company: $342M of revenue in its latest quarter (Q3 2026) against $340M for Corcept Therapeutics (Q3 2026).
Is Acadia Pharmaceuticals or Corcept Therapeutics growing faster?
Corcept Therapeutics is growing faster (+64% against +23% a year earlier).
Which is more profitable, Acadia Pharmaceuticals or Corcept Therapeutics?
Corcept Therapeutics is more profitable, with an operating margin of 33.7% against 21.0%.
More: Acadia Pharmaceuticals earnings · how Acadia Pharmaceuticals makes money · Corcept Therapeutics earnings · how Corcept Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.